Clinical Trial Update: FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial at University Hospital Tuebingen evaluating FusionVAC22_01, a fusion transcript-based peptide vaccine, in combination with immune check…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• FusionVAC22_01

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Fibrolamellar Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING